TargetMol

SB-269970 hydrochloride

Product Code:
 
TAR-T6655
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T6655-2mg2mg£111.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6655-1mL1 mL * 10 mM (in DMSO)£125.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6655-5mg5mg£125.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6655-10mg10mg£171.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6655-25mg25mg£287.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6655-50mg50mg£450.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
SB269970 HCl, a hydrochloride salt form of SB-269970, is a 5-HT7 receptor antagonist (pKi of 8.3) and exhibits >50-fold selectivity against other receptors.
CAS:
261901-57-9
Formula:
C18H29ClN2O3S
Molecular Weight:
388.95
Pathway:
Neuroscience; GPCR/G Protein
Purity:
0.98
SMILES:
Cl.CC1CCN(CC[C@H]2CCCN2S(=O)(=O)c2cccc(O)c2)CC1
Target:
5-HT Receptor

References

Galici R, et al. Behav Pharmacol, 2008, 19(2), 153-159. Roberts C, et al. Br J Pharmacol, 2001, 132(7), 1574-1580. Weso?owska A, et al. Neuropharmacology. 2006 Sep;51(3):578-86. Hagan JJ, et al. Br J Pharmacol, 2000, 130(3), 539-548. Galici R, et al. FASEB J, 2009, 23, Meeting Abstract Supplement, 586.6.